Detalhe da pesquisa
1.
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.
Am Heart J
; 274: 32-45, 2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38705341
2.
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.
Curr Atheroscler Rep
; 26(2): 35-44, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38133847
3.
The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease.
Pharmacol Res
; 197: 106972, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37898443
4.
Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels.
Int J Mol Sci
; 23(16)2022 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36012684
5.
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Am Heart J
; 170(1): 117-22, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26093872
6.
The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.
Eur Heart J
; 35(27): 1792-800, 2014 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24639426
7.
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib.
J Clin Pharmacol
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38720593
8.
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial.
J Atheroscler Thromb
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38569868
9.
CETP and SGLT2 inhibitor combination therapy improves glycemic control.
medRxiv
; 2023 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37398493
10.
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition.
Eur Heart J Cardiovasc Pharmacother
; 9(2): 148-155, 2023 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307922
11.
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.
J Clin Lipidol
; 17(4): 491-503, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37277261
12.
Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
Cardiovasc Res
; 118(14): 2919-2931, 2022 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34849601
13.
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial.
Nat Med
; 28(8): 1672-1678, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35953719
14.
Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate.
Am J Cardiol
; 97(11): 1602-6, 2006 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16728222
15.
Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.
Future Cardiol
; 12(4): 405-18, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27160944